TAK-448

Kisspeptin Receptor Agonist (Kiss1R / GPR54 Agonist)Rx: ResearchCompound: Investigational

Also known as: Kisspeptin analog TAK-448, RVX-TAK-448, TAK448

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

TAK-448 is an investigational kisspeptin receptor agonist developed by Takeda Pharmaceutical. It has a unique dual-phase pharmacology: acute dosing stimulates gonadotropin release, while chronic/continuous dosing suppresses the HPG axis analogous to GnRH agonists. It has been studied for potential use in hormone-sensitive cancers (prostate cancer), hypogonadotropic hypogonadism, and other reproductive endocrine disorders.

Mechanism of Action

TAK-448 is a potent, long-acting synthetic kisspeptin analog that acts as a full agonist at the kisspeptin receptor (Kiss1R/GPR54). Sustained activation of Kiss1R initially stimulates GnRH pulsatile release, but chronic administration leads to receptor desensitization and downregulation of the hypothalamic-pituitary-gonadal (HPG) axis, suppressing LH, FSH, and sex steroid production.

Routes of Administration

Subcutaneous

Goals & Uses

  • Stimulation of LH and FSH secretionReproductive EndocrinologyModerate
  • Male infertilityReproductive EndocrinologyLow
  • Treatment of hypogonadotropic hypogonadismEndocrinologyLow
  • Testosterone suppression in prostate cancerOncologyModerate

Contraindications

  • PregnancyPopulationHighPotential fetal risk or insufficient safety data
  • Hormone-sensitive conditions where sex steroid stimulation is contraindicatedOncologyHigh
  • Known hypersensitivity to kisspeptin analogsImmunologicalHigh

Adverse Effects

  • Injection site reactionsLocalCommon
  • Decreased libido / sexual dysfunctionSexual HealthCommon
  • Testosterone flareEndocrineCommon
  • Hot flushesVasomotorCommon
  • Bone mineral density reductionMusculoskeletalUncommon

Drug Interactions

  • Antiandrogens (e.g., enzalutamide, bicalutamide)Low
  • GnRH antagonists (e.g., degarelix)Moderate
  • GnRH agonists (e.g., leuprolide)Moderate

Population Constraints

  • Pediatric patientsAgeAbsolute
  • Patients with severe renal or hepatic impairmentOrgan ImpairmentRelative
  • Women of childbearing potentialReproductiveRelative

Regulatory Status

  • European UnionInvestigationalNo EMA approval; investigational status only.
  • United StatesInvestigationalStudied in Phase I/II clinical trials; no FDA approval as of available data.
  • United KingdomInvestigationalNo MHRA approval; investigational only.

TAK-448 has not received regulatory approval in any jurisdiction. It has been studied in Phase I/II clinical trials. Development status as of available data suggests it remains investigational.

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack